Dragonfly Therapeutics
Waltham
About Dragonfly Therapeutics
Dragonfly Therapeutics is a clinical-stage biotech developing novel first-in-class therapeutics targeted at natural killer cells and other cells of the innate immune system. These therapies are designed to counterbalance immune suppressive factors present in the tumor microenvironment and mobilize anti-cancer immune responses. Our molecules are expected to be potent as single agents as well as in treatment combinations with existing cancer immunotherapies. Our scientific founders are major figures in cancer biology and immunology and have launched Dragonfly to harness the power of the immune system to provide breakthrough cancer treatments for patients. For more information, email [email protected].
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 101 – 250
- Estimated revenue: $10K – $50K
- Last round: Series Unknown (Jan 2022)
- Website: dragonflytx.com
- Phone: (617)588-0086
Industries & Categories
Biotechnology, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/dragonfly-therapeutics-3459745 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.